Medasense & Nihon Kohden Pen Distribution Agreement

Medasense, a pain management technology company, today announced a strategic partnership with Nihon Kohden for exclusive distribution of its pain monitoring device in Japan, pending regulatory approval. The partnership will introduce Medasense’s nociception monitor to the market.

Its nociception monitor is a device which includes an AI powered NOL - Nociception Level Index, and real-time objective pain monitoring to personalize and optimize pain treatment. The NOL - Nociception Level Index quantifies the physiological response to pain, according to the company press release, with over 40 peer reviewed publications and clinical studies demonstrating “that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post-operative pain score and patient recovery.”

Its flagship product, the PMD-200 — commercially available in the US, Europe, Canada, Latin America, and Israel — uses this index, leveraging its advanced AI and proprietary non-invasive sensor system to objectively measure pain in patients in operating room or critical care settings unable to communicate.

Through the strategic agreement, the monitor will be accessible to hospitals and clinics throughout Japan using Nihon Kohden’s distribution channels, pending regulatory approval.

“We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions,” said Galit Zuckerman Medasense CEO and founder, in the release. " Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden's established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor."